Aptamer–drug conjugate: Targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity

International Journal of Nanomedicine

Volumn 13, Issue , 2018, Pages 763-776

  Dou, Xiao Qian ^a   Wang, Hua ^b   Zhang, Jing ^c   Wang, Fang ^c   Xu, Gui Li ^a   Xu, Cheng Cheng ^a   Xu, Huan Hua ^a   Xiang, Shen Si ^a   Fu, Jie ^a   Song, Hai Feng ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^c United Power Technology Co Ltd   (China)

Author keywords

Aptamer; Breast cancer; Cardiac toxicity; Doxorubicin; Drug conjugate; Human epidermal growth factor receptor 3; Targeted therapy

Indexed keywords

APTAMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ANTINEOPLASTIC ANTIBIOTIC; ERBB3 PROTEIN, HUMAN; LIPOSOME; MACROGOL DERIVATIVE; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APTAMER DRUG CONJUGATE TARGETED DELIVERY SYSTEM; ARTICLE; BINDING AFFINITY; BODY WEIGHT LOSS; BREAST CANCER; BT-474 CELL LINE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER TISSUE; CARDIOTOXICITY; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART INJURY; HEK293T CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; LIVER INJURY; MCF-7 CELL LINE; MOUSE; NONHUMAN; SURVIVAL RATE; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; FEMALE; METABOLISM; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APTAMERS, NUCLEOTIDE; CARDIOTOXICITY; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOSOMES; MCF-7 CELLS; MICE, INBRED BALB C; NANOPARTICLES; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-3; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85041535195     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S149887     Document Type: Article

References (30)

1. Singal PK, Liiskovic NS, Hill M, Thomas TP, Li T. Combination therapy with probucol prevents adriamycininduced cariomyopathy. Mol Cell Cardiol. 1995;27:1055–1063.
2. Fridrik MA, Jaeger U, Petzer A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: a randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14). Eur J Cancer. 2016; 58:112–121.
3. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Clin Cancer Res. 2000;6(12):4939–4949.
4. Yang J, Qiao L, Zeng Z, et al. The role of the ATM/Chk/P53 pathway in mediating DNA damage in hand-foot syndrome induced by PLD. Toxicol Lett. 2017;4(265):131–139.
5. Yokomichi N, Nagasawa T, Coler-Reilly A, et al. Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell. 2013;26(1):8–18.
6. Rohlfing S, Aurich M, Schöning T, Ho AD, Witzens-Harig M. Nonpegy-lated liposomal Doxorubicin as a component of R-CHOP is an effective and safe alternative to conventional Doxorubicin in the treatment of patients with diffuse large B-cell lymphoma and preexisting cardiac diseases. Clin Lymphoma Myeloma Leuk. 2015;15(8):458–463.
7. Callahan R. Ado-trastuzumab emtansine in metastatic HER2-positive breast cancer. J Adv Pract Oncol. 2014;5(2):134–139.
8. Uppal H, Doudement E, Mahapatra K, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015;21(1):123–133.
9. Chen K, Liu B, Yu B, et al. Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(3):Epub Oct 31, 2016.
10. Zhao N, Pei SN, Qi J, et al. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials. 2015; 67:42–51.
11. Zhu CL, Song XY, Zhou WH, Yang HH, Wen YH, Wang XR. An efficient cell-targeting and intracellular controlled-release drug delivery system based on MSN-PEM-aptamer conjugates. J Mater Chem. 2009; 19:7765–7770.
12. Gala K, Chandarlapaty S. Molecular pathways: HER3 targeted therapy. Clin Cancer Res. 2014;20(6):1410–1416.
13. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancertherapy. Clin Cancer Res. 2010;16(5):1373–1383.
14. Zhang J, Zhang X, Liu Q, et al. Mammalian cell display for rapid screening scFv antibody therapy. Acta Biochim Biophys Sin. 2014;46(10): 859–866.
15. Liu YJ, Dou XQ, Wang F, et al. IL-4RJ aptamer-liposome-CpG oligodeoxynucleotides suppress tumour growth by targeting the tumour microenvironment. J Drug Target. 2016;1:1–9.
16. Dicheva BM, Seynhaeve AL, Soulie T, Eggermont AM, Ten Hagen TL, Koning GA. Pharmacokinetics, tissue distribution and therapeutic effect of cationic thermosensitive liposomal doxorubicin upon mild hyperthermia. Pharm Res. 2016;33(3):627–638.
17. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–164.
18. Kim JH, Im KS, Kim NH, Yhee JY, Nho WG, Sur JH. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study. Vet J. 2011; 189(3):318–322.
19. Trocmé E, Mougiakakos D, Johansson CC, et al. Nuclear HER3 is associated with favorable overall survival in uveal melanoma. Int J Cancer. 2012;130(5):1120–1127.
20. Little field P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal. 2014;7(354):ra114.
21. Bielack SS, Erttmann R, Winkler K, Landbeck G. Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol. 1989;25(5):873–882.
22. 2 in patients with recurrent ovarian and peritoneal cancer. Int J Gynecol Cancer. 2008;18(2): 223–227.
23. Yuan Y, Orlow SJ, Curtin J, Downey A, Muggia F. Pegylated liposomal doxorubicin (PLD): enhanced skin toxicity in areas of vitiligo. Ecancermedicalscience. 2008;2:111.
24. Shimada M, Sato S, Otsuki T, et al. Supportive care for hand-foot syndrome and stomatitis in relapsed ovarian cancer patients receiving pegylated liposomal doxorubicin. J Clin Oncol. 2011;29:e19722.
25. von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S, Waggoner S. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 2010;116(20):4735–4743.
26. Zaja F, Tomadini V, Zaccaria A, et al. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patientswith diffuse large B-cell lymphoma. Leuk Lymphoma. 2006;47(10):2174–2180.
27. Oki Y, Ewer MS, Lenihan DJ, et al. Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk. 2015; 15(3):152–158.
28. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017; 9(2):12.
29. Lee CH, Lee SH, Kim JH, Noh YH, Noh GJ, Lee SW. Pharmacokinetics of a cholesterol-conjugated aptamer against the hepatitis C virus (HCV) NS5B protein. Mol Ther Nucleic Acids. 2015;4(10):e254.
30. Leal M, Wentland J, Han X, et al. Preclinical development of an anti-5T4 antibody−drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice. Bioconjug Chem. 2015;26(11): 2223–2232.